Clinical Trials
21 trialsNCT02506959 2025-03-18
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02654990 2024-07-12
PANORAMA_3
pharmaand GmbH
Phase 2 Completed
NCT01301807 2023-09-29
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04150289 2023-06-15
RECOMM
pharmaand GmbH
Completed
NCT02722941 2022-11-01
Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01658241 2022-05-06
VEG VCA1
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT01496118 2022-02-02
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT01965353 2021-09-05
PanRVD
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00621244 2021-01-05
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
Novartis
Phase 1/2 Completed
NCT00532389 2020-12-19
Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
Novartis
Phase 1 Completed
NCT00532675 2020-12-19
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
Novartis
Phase 1 Completed
NCT01023308 2020-03-17
PANORAMA-1
Novartis
Phase 3 Completed
NCT00918333 2020-03-10
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT02057640 2019-12-11
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT02290431 2019-11-18
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Novartis
Phase 2 Completed
NCT01440582 2019-03-04
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01549431 2019-01-16
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
Emory University
Phase 1 Completed
NCT01651039 2018-04-09
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT01083602 2017-12-21
MACS1271
Novartis
Phase 2 Completed
NCT00743288 2014-05-08
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
Oncotherapeutics
Phase 1/2 Completed
NCT00962507 2013-02-15
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed